WHO's Anti-Tobacco Marketing Campaign: Protecting Youth from Harm

Aug.02.2022
WHO warns of 40 million young people using tobacco worldwide, with harmful effects on health and mortality rates.

The World Health Organization (WHO) has revealed that over 40 million young people aged 13-15 have started using tobacco, a shocking statistic that highlights the urgent need for action to prevent the harmful effects of this behavior. In response, the WHO has launched a global initiative to expose the tobacco industry's "strategic, aggressive and well-resourced tactics" that target young people, and to equip them with the knowledge and tools to resist these strategies. This anti-marketing campaign aims to strengthen efforts to reduce tobacco demand and implement effective policies worldwide. The tobacco industry has been utilizing new trends to target younger populations, particularly through the use of marketing strategies that encourage the use of new products like e-cigarettes and heated tobacco. However, these products have been proven to be equally harmful as traditional cigarettes, with the same carcinogenic compounds and toxins present in their tobacco content. The variety of flavors available, such as bubblegum and candy, are designed to attract younger audiences and increase the likelihood of them becoming regular smokers later in life. Smoking-related illnesses caused by tobacco result in over 7 million deaths worldwide each year, with approximately 900,000 dying from tobacco smoke-related diseases. Of all smoking-related deaths, more than 40% are from lung cancer, chronic respiratory diseases, and tuberculosis, among other lung-related illnesses.


In 2017, Guyana passed a tobacco control law that follows several provisions of the World Health Organization's convention and aims to become one of the most comprehensive tobacco control laws by implementing a series of policies. These policies include providing a 100% smoke-free environment in all indoor public places, indoor workplaces, public transportation, and designated outdoor areas to prevent people from being exposed to tobacco smoke. It also prohibits all forms of tobacco product advertising, promotion, and sponsorship and requires 60% of tobacco product packaging to display health warning labels, including pictures. Additionally, the law includes a ban on selling tobacco products to minors, selling tobacco products through vending machines, manufacturing and selling toys, candies, and any other tobacco product-shaped commodities. However, there is still much work to be done in fighting against tobacco, as 78% of deaths in Guyana are caused by non-communicable diseases (NCDs), some of which are closely related to tobacco use. While enacting necessary legislation is a good starting point, Guyana's health authorities must address many other challenges if they truly want to reduce the number of people who die or become ill due to tobacco use or exposure. These challenges include monitoring and compliance, stricter enforcement of the law to ensure people are protected from the harms of tobacco use, and addressing the recent trend of highly appealing new tobacco alternatives for young people.


This article is compiled from third-party information and is intended for industry communication and learning.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of its content. The translation of this article is solely for industry exchange and research purposes.


Due to limitations in the translation process, the translated article may not fully capture the original expression. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related expressions and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Multi-State Coalition Urges F1 to End Nicotine Sponsorships, Citing Zyn and Velo
Multi-State Coalition Urges F1 to End Nicotine Sponsorships, Citing Zyn and Velo
Hawaii Attorney General Anne Lopez is co-leading a coalition of 19 states and jurisdictions urging the Fédération Internationale de l’Automobile (FIA) and Formula 1 to end sponsorships involving tobacco and nicotine products, including nicotine pouch brands such as Zyn and Velo.
News
Jun.09
RJR Vapor Loses Tax Refund Case as Texas High Court Finds VELO Pouches Taxable
RJR Vapor Loses Tax Refund Case as Texas High Court Finds VELO Pouches Taxable
The Texas Supreme Court issued a case summary on May 8, 2026, describing its decision in Hancock v. RJR Vapor Co. LLC. The dispute centered on whether RJR Vapor’s VELO oral nicotine pouches are taxable as “tobacco products” under the Texas Tax Code. Lower courts had held that the pouches were not taxable tobacco products, but the Texas Supreme Court reversed, concluding that VELO pouches are taxable because they are made of “a tobacco substitute.”
May.09 by 2FIRSTS.ai
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
2Firsts Exclusive Analysis | RLX Q1 Revenue Rises 96.2%, International Business Points to a More Integrated Global Strategy
2Firsts Exclusive Analysis | RLX Q1 Revenue Rises 96.2%, International Business Points to a More Integrated Global Strategy
RLX Technology’s Q1 net revenues rose 96.2% year over year, with international business accounting for 72.3% of total revenue. Beyond the headline growth, the results point to deeper globalization: European operations, Nexus supply-chain integration and a broader product portfolio are becoming key signals to watch.
Special Report
May.20
PML Expands Its UK Smoke-Free Portfolio With LEVIA
PML Expands Its UK Smoke-Free Portfolio With LEVIA
Philip Morris Limited has launched LEVIA, a new range of zero-tobacco flavored nicotine sticks created for the IQOS ILUMA range. The product expands the company’s smoke-free portfolio in the UK and will initially be available in four variants, including Deep Mint and three capsule-based flavors. LEVIA has a recommended retail price of £5, or about $6.73, based on the European Central Bank’s April 28.
Apr.29 by 2FIRSTS.ai
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA Tobacco Center Pushes Review-Efficiency Statement After Commissioner’s Exit
FDA CTP issued a May 7 statement on accelerating product review and improving PMTA efficiency, but did not push it via official X and newsletter until May 13, one day after FDA Commissioner Marty Makary’s resignation was confirmed. FDA has not explained the delay, and no public evidence links it directly to the leadership change. The timing is notable given CTP’s usual 24-hour distribution practice.
Special Report
May.14